178 related articles for article (PubMed ID: 31304622)
1. Dysfunctional striatal dopamine signaling in Huntington's disease.
Koch ET; Raymond LA
J Neurosci Res; 2019 Dec; 97(12):1636-1654. PubMed ID: 31304622
[TBL] [Abstract][Full Text] [Related]
2. Dopamine and glutamate in Huntington's disease: A balancing act.
André VM; Cepeda C; Levine MS
CNS Neurosci Ther; 2010 Jun; 16(3):163-78. PubMed ID: 20406248
[TBL] [Abstract][Full Text] [Related]
3. Dopaminergic signaling and striatal neurodegeneration in Huntington's disease.
Tang TS; Chen X; Liu J; Bezprozvanny I
J Neurosci; 2007 Jul; 27(30):7899-910. PubMed ID: 17652581
[TBL] [Abstract][Full Text] [Related]
4. Impaired Replenishment of Cortico-Striatal Synaptic Glutamate in Huntington's Disease Mouse Model.
Buren C; Tu G; Raymond LA
J Huntingtons Dis; 2020; 9(2):149-161. PubMed ID: 32310183
[TBL] [Abstract][Full Text] [Related]
5. Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease.
Ferrante A; Martire A; Pepponi R; Varani K; Vincenzi F; Ferraro L; Beggiato S; Tebano MT; Popoli P
Neurobiol Dis; 2014 Nov; 71():193-204. PubMed ID: 25132555
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of synaptic dysfunction and excitotoxicity in Huntington's disease.
Sepers MD; Raymond LA
Drug Discov Today; 2014 Jul; 19(7):990-6. PubMed ID: 24603212
[TBL] [Abstract][Full Text] [Related]
7. Mitigation of augmented extrasynaptic NMDAR signaling and apoptosis in cortico-striatal co-cultures from Huntington's disease mice.
Milnerwood AJ; Kaufman AM; Sepers MD; Gladding CM; Zhang L; Wang L; Fan J; Coquinco A; Qiao JY; Lee H; Wang YT; Cynader M; Raymond LA
Neurobiol Dis; 2012 Oct; 48(1):40-51. PubMed ID: 22668780
[TBL] [Abstract][Full Text] [Related]
8. Comparison of phosphodiesterase 10A, dopamine receptors D1 and D2 and dopamine transporter ligand binding in the striatum of the R6/2 and BACHD mouse models of Huntington's disease.
Miller S; Hill Della Puppa G; Reidling J; Marcora E; Thompson LM; Treanor J
J Huntingtons Dis; 2014; 3(4):333-41. PubMed ID: 25575954
[TBL] [Abstract][Full Text] [Related]
9. Reduced Expression of Foxp1 as a Contributing Factor in Huntington's Disease.
Louis Sam Titus ASC; Yusuff T; Cassar M; Thomas E; Kretzschmar D; D'Mello SR
J Neurosci; 2017 Jul; 37(27):6575-6587. PubMed ID: 28550168
[TBL] [Abstract][Full Text] [Related]
10. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
[TBL] [Abstract][Full Text] [Related]
11. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019
[TBL] [Abstract][Full Text] [Related]
12. Mass Spectrometry Analysis of Wild-Type and Knock-in Q140/Q140 Huntington's Disease Mouse Brains Reveals Changes in Glycerophospholipids Including Alterations in Phosphatidic Acid and Lyso-Phosphatidic Acid.
Vodicka P; Mo S; Tousley A; Green KM; Sapp E; Iuliano M; Sadri-Vakili G; Shaffer SA; Aronin N; DiFiglia M; Kegel-Gleason KB
J Huntingtons Dis; 2015; 4(2):187-201. PubMed ID: 26397899
[TBL] [Abstract][Full Text] [Related]
13. Dysregulation of Corticostriatal Connectivity in Huntington's Disease: A Role for Dopamine Modulation.
Rangel-Barajas C; Rebec GV
J Huntingtons Dis; 2016 Dec; 5(4):303-331. PubMed ID: 27983564
[TBL] [Abstract][Full Text] [Related]
14. Enhanced striatopallidal gamma-aminobutyric acid (GABA)
Perez-Rosello T; Gelman S; Tombaugh G; Cachope R; Beaumont V; Surmeier DJ
Mov Disord; 2019 May; 34(5):684-696. PubMed ID: 30726572
[TBL] [Abstract][Full Text] [Related]
15. Striatal Mutant Huntingtin Protein Levels Decline with Age in Homozygous Huntington's Disease Knock-In Mouse Models.
Franich NR; Basso M; André EA; Ochaba J; Kumar A; Thein S; Fote G; Kachemov M; Lau AL; Yeung SY; Osmand A; Zeitlin SO; Ratan RR; Thompson LM; Steffan JS
J Huntingtons Dis; 2018; 7(2):137-150. PubMed ID: 29843246
[TBL] [Abstract][Full Text] [Related]
16. Dysregulation of corticostriatal ascorbate release and glutamate uptake in transgenic models of Huntington's disease.
Rebec GV
Antioxid Redox Signal; 2013 Dec; 19(17):2115-28. PubMed ID: 23642110
[TBL] [Abstract][Full Text] [Related]
17. The Complexity of Clinical Huntington's Disease: Developments in Molecular Genetics, Neuropathology and Neuroimaging Biomarkers.
Tippett LJ; Waldvogel HJ; Snell RG; Vonsattel JP; Young AB; Faull RLM
Adv Neurobiol; 2017; 15():129-161. PubMed ID: 28674980
[TBL] [Abstract][Full Text] [Related]
18. SPECT study of the nigrostriatal dopaminergic system in Huntington's disease.
Hwang WJ; Yao WJ
J Neuroimaging; 2013 Apr; 23(2):192-6. PubMed ID: 22211920
[TBL] [Abstract][Full Text] [Related]
19. Synaptic pathology in Huntington's disease: Beyond the corticostriatal pathway.
Barry J; Bui MTN; Levine MS; Cepeda C
Neurobiol Dis; 2022 Jan; 162():105574. PubMed ID: 34848336
[TBL] [Abstract][Full Text] [Related]
20. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease.
Hermel E; Gafni J; Propp SS; Leavitt BR; Wellington CL; Young JE; Hackam AS; Logvinova AV; Peel AL; Chen SF; Hook V; Singaraja R; Krajewski S; Goldsmith PC; Ellerby HM; Hayden MR; Bredesen DE; Ellerby LM
Cell Death Differ; 2004 Apr; 11(4):424-38. PubMed ID: 14713958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
